DeCure for Chronic inflammatory demyelinating polyradiculoneuropathy
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for chronic inflammatory demyelinating polyradiculoneuropathy — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChronic inflammatory demyelinating polyradiculoneuropathy maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chronic inflammatory demyelinating polyradiculoneuropathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Fc gamma receptor and transporter (FCGRT) — FCGRT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cysdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6C98 · 1.85 Å · ligand CYSTEINE (CYS). Experimental structure, not a prediction.
What the evidence adds up to
In a 10-year follow-up of 60 patients (35 men, 25 women) diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy, 56 of 59 treated patients (94.9%) initially responded to immunosuppressive therapy. The average time to first improvement was 1.9 months (SD 3.6), and the average time to reach a clinical plateau was 6.6 months (SD 5.4). Despite this high initial response rate, only 24 patients (40%) were in partial or complete remission and receiving no medication at the end of follow-up. Two patients died. The course was monophasic in 32 patients (53.3%) and relapsing in 28 (46.6%). No clinical or laboratory features at diagnosis predicted outcome.
Three case reports describe patients in whom mononeuropathic limb weakness developed 2, 11, and 23 years before the onset of generalised polyradiculoneuropathy. The eventual diagnosis of CIDP remained uncertain until other causes were excluded and the disorder progressed to other limbs. This focal or regional variant appears to account for a small number of CIDP cases.
A 2024 literature review notes that the European Academy of Neurology recommends corticosteroids, immunoglobulin, and plasma exchange as treatment options. The same review states that haematopoietic stem cell transplantation and spinal cord stimulation show potential as therapeutic options, but provides no patient numbers, response rates, or survival data from any study. A separate 2024 case description emphasises that patients require close follow-up because demyelination is accompanied by axonal degeneration, and that timely adjustment of treatment is needed to prevent irreversible axonal damage.
What is still missing are prospective trials that stratify patients by clinical subtype (monophasic versus relapsing, focal versus generalised) and that report long-term outcomes beyond initial response. No randomised controlled data exist for the newer interventions mentioned in the review, and no biomarkers have been identified that predict which patients will achieve sustained remission off medication.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractOver a 10-year period, we followed up 60 patients (35 men and 25 women) with chronic inflammatory demyelinating polyradiculoneuropathy. Diagnosis was based on previously outlined criteria. Patients were treated in a uniform manner and the overwhelming majority, 56 (94.9%) of 59 treated patients, initially responded to immunosuppressive therapy. The time for initial improvement was 1.9 +/- 3.6 months while the time to reach a clinical plateau was 6.6 +/- 5.4 months. The course was monophasic in 32 patients (53.3%) and relapsing in 28 (46.6%). Despite the initial responsiveness, only 24 (40%) of 60 patients are in partial or complete remission, receiving no medication. Two patients died. We were unable to identify specific clinical or laboratory features at the time of diagnosis that predicted outcome. Our data analysis, along with previous reports, suggests that chronic inflammatory demyelinating polyradiculoneuropathy may be more heterogeneous than previously emphasized. In this light, we have proposed diagnostic criteria that allow for the heterogeneity but at the same time provide for a more consistent approach to better establish the natural history of this condition.
Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years
AbstractWe report three patients who exhibited an unusual clinical course of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in which mononeuropathic limb weakness developed 2, 11 and 23 years, respectively, before the development of generalized polyradiculoneuropathy. The eventual diagnosis remained uncertain until other causes of neuropathy were excluded, and the clinical disorder progressed to involve the other limbs. Focal or regional variants of CIDP suggest that the pathologic, and perhaps the immunologic, abnormalities can be localized and selective for prolonged periods of time. Although this clinical variant seems to account for a small number of CIDP cases, its recognition may aid in making an early diagnosis.
Clinical Case Reports · 2024 · 0 citations · open access
Chronic inflammatory demyelinating polyneuropathy. A case description
AbstractPatients affected by chronic inflammatory demyelinating polyradiculoneuropathy require close follow up due to the neuronal demyelination along with axonal degeneration associated with the disease process, giving the opportunity to the medical team of adequating therapeutics and other medical interventions, according to the evolution of the symptoms, to prevent irreversible axonal degeneration.
Current Therapies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Literature Review
AbstractChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease. The European Academy of Neurology recommends treatment using corticosteroids, immunoglobulin, plasma exchange, & other treatments as treatment options for chronic inflammatory demyelinating polyradiculoneuropathy. However, several studies in recent years have shown that there is potential in the treatment of chronic inflammatory demyelinating Polyradiculoneuropathy. The aim of this literature review is to provide the latest therapy for chronic inflammatory demyelinating polyradiculoneuropathy based on guidelines as well as other information therapy alternatives. The method used in this literature review uses searches in several databases. The results of several studies show the development of chronic inflammatory demyelinating polyradiculoneuropathy therapy both pharmacologically & non-pharmacologically. The development of therapy for chronic inflammatory demyelinating polyradiculoneuropathy, namely hematopoietic stem cells & spinal cord stimulation, shows potential as a therapeutic option for patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
